Sep 2026· Naunyn-Schmiedeberg's Archives of Pharmacology· 0 citations· 33 references
Medicine
Abstract
Sleep disorders present major public health issues because of their associations with chronic diseases. Despite extensive research efforts, the underlying biological mechanisms remain inadequately understood. We performed bidirectional two-sample Mendelian randomization (MR) to investigate relationships between sleep disorders and common brain diseases, followed by summary-data-based Mendelian randomization (SMR), heterogeneity in dependent instruments (HEIDI), and colocalization analyses integrating protein quantitative trait locus (pQTL) and expression quantitative trait locus (eQTL) data to prioritize genetically supported candidate genes. Compound-gene associations were subsequently evaluated, and selected clinically used compounds underwent exploratory molecular docking and molecular dynamics simulation. Two-step MR mediation analyses and MR phenome-wide association study (MR-PheWAS) were used to investigate potential mediating traits and broader phenotypic associations. Multi-omic genetic analyses prioritized six candidate genes-BCAN, HDGF, MEPE, PAM, PRR4, and IGLON5-with BCAN, HDGF, and MEPE showing the strongest genetic support. Compound prioritization retained four clinically used drugs associated with the candidate genes for structure-based assessment. Exploratory molecular docking yielded the most favorable predicted Vina score for the BCAN-danazol pair, and molecular dynamics simulation showed persistent local BCAN-danazol contacts despite substantial global conformational rearrangement of BCAN during the trajectory. Mediation analyses identified several risk factors, cerebrospinal fluid metabolites, and structural connectivity measures showing statistical evidence consistent with partial mediation of selected gene/protein-sleep disorder associations. MR-PheWAS further characterized broader phenotypic associations of the genetically supported genes. Integrating genetic and multi-omic evidence identified candidate molecular targets and compound-gene associations relevant to sleep disorders. These findings provide hypotheses for subsequent functional and pharmacological validation.
These findings implicate key mitochondrial genes, particularly DCXR and ACADVL, in the pathophysiology of specific sleep disorder subtypes, highlighting potential avenues for precision medicine.
Jun-Jun Xu, Zi-Ya Zhang, Liu-Yang Yu et al.· Journal of Molecular Neurosc...· 0 citations
STUDY OBJECTIVES
Obstructive sleep apnea (OSA) remains a prevalent sleep disorder with incompletely characterized molecular mechanisms and evolving pharmacological options. We aimed to identify molecular biomarkers associated with OSA and prioritize candidates for further evaluation.
METHODS
OSA genome-wide associati...
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Current pharmacological treatments have limitations, highlighting the need for new therapeutic targets. Using two-sample Mendelian randomization with cis-expression quantitative trait loci from the eQTLGen Consortium (31,684 indiv...
Pei Pei, Shu-Wen Lu, Wei-Jie Yu et al.· Twin Research and Human Gene...· 0 citations
This exploratory study integrates pilot-scale metabolomics with genetic analyses to identify candidate metabolic signals and inflammatory pathways linked to PD and indicated that SULT1A1 may partially mediate the association between 3-phenylpropionylglycine and PD.
INTRODUCTION
Bipolar Disorder (BD) is a severe psychiatric condition with high heritability and clinical heterogeneity. Despite numerous genetic variants linked to BD through Genome- Wide Association Studies (GWAS), the molecular mechanisms and effective therapeutic targets remain unclear. This study aims to identify p...
Yan-Ting Jin, Tian-Yu Zhang, Chang-Cheng Xiang et al.· Current Drug Targets· 0 citations
The findings provide a systematic, genetically-informed prioritisation of plasma proteins as causal molecular exposures in MS by integrating analyses across traits that often co-occur with MS, and distinguish proteins with MS-specific effects from those with effects across multiple phenotypes.
Matthew Boyton, G. Khandaker, V. Walker et al.· Wellcome Open Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.